N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review - PubMed

Review

N-acetylcysteine (NAC) and Its Role in Clinical Practice Management of Cystic Fibrosis (CF): A Review

Marta Guerini et al. Pharmaceuticals (Basel). 2022.

Abstract

N-acetylcysteine is the acetylated form of the amino acid L-cysteine and a precursor to glutathione (GSH). It has been known for a long time as a powerful antioxidant and as an antidote for paracetamol overdose. However, other activities related to this molecule have been discovered over the years, making it a promising drug for diseases such as cystic fibrosis (CF). Its antioxidant activity plays a key role in CF airway inflammation and redox imbalance. Furthermore, this molecule appears to play an important role in the prevention and eradication of biofilms resulting from CF airway infections, in particular that of Pseudomonas aeruginosa. The aim of this review is to provide an overview of CF and the role that NAC could play in preventing and eliminating biofilms, as a modulator of inflammation and as an antioxidant, restoring the redox balance within the airways in CF patients. To do this, NAC can act alone, but it can also be used as an adjuvant molecule to known drugs (antibiotics/anti-inflammatories) to increase their activity.

Keywords: N-acetylcysteine; biofilm; cystic fibrosis; lung diseases; oxidative stress; pseudomonas aeruginosa.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Similar articles

• Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits.

  Rushworth GF, Megson IL. Rushworth GF, et al. Pharmacol Ther. 2014 Feb;141(2):150-9. doi: 10.1016/j.pharmthera.2013.09.006. Epub 2013 Sep 28. Pharmacol Ther. 2014. PMID: 24080471 Review.

• Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.

  Lababidi N, Ofosu Kissi E, Elgaher WAM, Sigal V, Haupenthal J, Schwarz BC, Hirsch AKH, Rades T, Schneider M. Lababidi N, et al. J Control Release. 2019 Nov 28;314:62-71. doi: 10.1016/j.jconrel.2019.10.038. Epub 2019 Oct 22. J Control Release. 2019. PMID: 31654686

• The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study.

  Skov M, Pressler T, Lykkesfeldt J, Poulsen HE, Jensen PØ, Johansen HK, Qvist T, Kræmer D, Høiby N, Ciofu O. Skov M, et al. J Cyst Fibros. 2015 Mar;14(2):211-8. doi: 10.1016/j.jcf.2014.09.015. Epub 2014 Oct 23. J Cyst Fibros. 2015. PMID: 25458464 Clinical Trial.

• The effect of N-acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections.

  Blasi F, Page C, Rossolini GM, Pallecchi L, Matera MG, Rogliani P, Cazzola M. Blasi F, et al. Respir Med. 2016 Aug;117:190-7. doi: 10.1016/j.rmed.2016.06.015. Epub 2016 Jun 16. Respir Med. 2016. PMID: 27492531 Review.

• Disruption of biofilms and killing of Burkholderia cenocepacia from cystic fibrosis lung using an antioxidant-antibiotic combination therapy.

  Aiyer A, Manoharan A, Paino D, Farrell J, Whiteley GS, Kriel FH, Glasbey TO, Manos J, Das T. Aiyer A, et al. Int J Antimicrob Agents. 2021 Aug;58(2):106372. doi: 10.1016/j.ijantimicag.2021.106372. Epub 2021 Jun 8. Int J Antimicrob Agents. 2021. PMID: 34116184

Cited by

• New Antimicrobial Strategies to Treat Multi-Drug Resistant Infections Caused by Gram-Negatives in Cystic Fibrosis.

  Scoffone VC, Barbieri G, Irudal S, Trespidi G, Buroni S. Scoffone VC, et al. Antibiotics (Basel). 2024 Jan 11;13(1):71. doi: 10.3390/antibiotics13010071. Antibiotics (Basel). 2024. PMID: 38247630 Free PMC article. Review.

• Changing Perspectives from Oxidative Stress to Redox Signaling-Extracellular Redox Control in Translational Medicine.

  Loreto Palacio P, Godoy JR, Aktas O, Hanschmann EM. Loreto Palacio P, et al. Antioxidants (Basel). 2022 Jun 16;11(6):1181. doi: 10.3390/antiox11061181. Antioxidants (Basel). 2022. PMID: 35740078 Free PMC article. Review.

• Impact of Nebulized BromAc^® on Mucus Plug Clearance in a Mechanically Ventilated Ex Vivo Ovine Lung Model of Obstructive Respiratory Conditions.

  Valle N, Eapen MS, Pillai K, Morris R, Akhter J, Mekkawy AH, Morris DL, Valle SJ. Valle N, et al. Life (Basel). 2024 Sep 3;14(9):1111. doi: 10.3390/life14091111. Life (Basel). 2024. PMID: 39337895 Free PMC article.

• N-Acetylcysteine Suppresses Microglial Inflammation and Induces Mortality Dose-Dependently via Tumor Necrosis Factor-α Signaling.

  Sakai M, Yu Z, Taniguchi M, Picotin R, Oyama N, Stellwagen D, Ono C, Kikuchi Y, Matsui K, Nakanishi M, Yoshii H, Furuyashiki T, Abe T, Tomita H. Sakai M, et al. Int J Mol Sci. 2023 Feb 14;24(4):3798. doi: 10.3390/ijms24043798. Int J Mol Sci. 2023. PMID: 36835209 Free PMC article.

• Exploring the Relationship between Mood Disorders and Coexisting Health Conditions: The Focus on Nutraceuticals.

  Mechlińska A, Wiglusz MS, Słupski J, Włodarczyk A, Cubała WJ. Mechlińska A, et al. Brain Sci. 2023 Aug 30;13(9):1262. doi: 10.3390/brainsci13091262. Brain Sci. 2023. PMID: 37759862 Free PMC article. Review.

References

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • MDPI
  • PubMed Central